Merck Survey Highlights HIV Knowledge Gaps
HIV Misinformation Persists Among Millennials, African Americans
Executive Summary
New options for the treatment and prevention of HIV/AIDs in recent years have not erased lingering stigmas and misinformation about the disease, especially among younger black communities in the US. Advocates hope that greater awareness of “U=U,” or “undetectable equals untransmittable,” can help to address ongoing discrimination and disparities.
You may also be interested in...
Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts
Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.
Exit Interview: Ken Kaitin On 35 Years At Tufts Center For Study Of Drug Development
At the end of December 2020, Kenneth Kaitin retired as director of the Tufts Center for the Study of Drug Development after 23 years in the role, and 35 years working with the CSDD. Kenneth Getz, previously professor and deputy director of the CSDD, succeeds Kaitin as director in 2021.
Need a specific report? 1000+ reports available
Buy Reports